Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:01 AM
Ignite Modification Date:
2025-12-25 @ 12:01 AM
NCT ID:
NCT00438958
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of one of the following hematologic malignancies:
* Acute myeloid leukemia in first complete remission or second complete remission
* Chronic myeloid leukemia in chronic or accelerated phase
* Myelodysplasia, including any of the following:
* Refractory anemia (RA)
* RA with ringed sideroblasts
* RA with excess blasts (RAEB) I
* RAEB in transformation
* Chronic myelomonocytic leukemia
* Other hematologic malignancy for which sibling donor stem cell transplantation with a myeloablative conditioning regimen is appropriate, including any of the following:
* Indolent non-Hodgkin's lymphoma (NHL)
* Aggressive NHL
* Chronic lymphocytic leukemia
* Hodgkin's lymphoma
* Myelofibrosis
* Hematologic malignancy not otherwise specified
* HLA-matched sibling donor available meeting all of the following criteria:
* 6/6 HLA match
* HLA typing performed by serologic or DNA methodology for A and B and by DNA methodology for DRB1 (intermediate resolution)
* Not identical twin with patient
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No cognitive, linguistic, or emotional difficulty that would preclude participation in the quality-of-life component of the study
* Able to communicate in English or French
* No HIV antibody positivity
PRIOR CONCURRENT THERAPY:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
16 Years
Maximum Age:
65 Years
Study:
NCT00438958
Study Brief:
Protocol Section:
NCT00438958